Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticlePsoriatic Arthritis

Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity

Leslie R. Harrold, Bradley S. Stolshek, Sabrina Rebello, David H. Collier, Alex Mutebi, Sally W. Wade, Wendi Malley, Jeffrey D. Greenberg and Carol J. Etzel
The Journal of Rheumatology January 2018, 45 (1) 78-82; DOI: https://doi.org/10.3899/jrheum.161567
Leslie R. Harrold
From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Leslie.Harrold@umassmed.edu
Bradley S. Stolshek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Rebello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Collier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Mutebi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally W. Wade
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendi Malley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey D. Greenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol J. Etzel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. Rebound may occur in patients with psoriatic arthritis (PsA) who discontinue TNF inhibitor (TNFi) therapy in low disease activity (LDA).

Methods. Using physician and patient reports, we quantified rebound following TNFi discontinuation [defined as Clinical Disease Activity Index (CDAI) score > 10 or TNFi restart] and time to rebound in adults with PsA in LDA (CDAI score ≤ 10) at TNFi discontinuation.

Results. Rebound occurred in 73% (69/94) of patients soon after discontinuation (median time to rebound 8.0 mos, 95% CI 6.0–12.0).

Conclusion. Rebound occurred frequently in patients with PsA after TNFi discontinuation. TNFi discontinuation after achieving LDA should be carefully considered.

Key Indexing Terms:
  • PSORIATIC ARTHRITIS
  • ANTIRHEUMATIC AGENTS
  • TUMOR NECROSIS FACTOR-α

Psoriatic arthritis (PsA) is a chronic, systemic, inflammatory disease affecting both the joints and skin1. Up to 40% of patients with psoriasis develop PsA; in the United States, PsA prevalence is estimated between 0.02% and 0.25% in the overall population2,3,4. Patients with PsA typically have arthritis, dactylitis, enthesitis, nail disease, and/or psoriasis, and have an increased risk for comorbid conditions, including metabolic syndrome and other conditions that contribute to cardiovascular disease risk (hypertension, hyperlipidemia, diabetes, obesity)3,5. The pain, functional and cosmetic impairments, and treatment side effects experienced by patients with PsA have been linked to increased direct costs, and decreased health-related quality of life, longterm work disability, and productivity losses6,7,8.

Symptoms and their severity may vary among patients with PsA over time2. PsA has a diverse clinical manifestation, and the primary treatment goals are to help patients reach low/minimal disease activity or remission to preserve or improve functionality, prevent irreversible structural joint damage, and to minimize the effect of comorbidities9,10. Treatment options for PsA include nonsteroidal antiinflammatory drugs as first-line therapies, and nonbiologic (nbDMARD) and biologic disease-modifying antirheumatic drugs (bDMARD), including tumor necrosis factor inhibitors (TNFi), interleukin (IL)-17 and IL-12/23, and small molecules (e.g., phosphodiesterase, Janus kinase inhibitors) as second-line therapies9. TNFi [adalimumab (ADA), etanercept (ETN), golimumab (GOL), infliximab (IFX)] are the first recommended bDMARD and these agents have long demonstrated effectiveness in reducing disease activity and controlling joint damage in patients with PsA, and more recently have been associated with lower risk of cardiovascular events in both psoriasis and PsA patients9,11. Little is known about clinical outcomes following treatment discontinuation after attaining low disease activity (LDA) or symptom remission. Therefore, our current study evaluated the rebound in disease activity (i.e., loss of initially attained LDA) and time to rebound in patients with PsA who discontinued TNFi therapy after achieving LDA.

MATERIALS AND METHODS

We analyzed retrospective data for patients with PsA who participated in the Corrona registry. Corrona is a large, US-based, independent, prospective, observational, disease-based registry with about 500 rheumatologists and 6000 patients with PsA participating since 2001. Patients are enrolled in the registry by their rheumatologists. Institutional review board (IRB) approvals for this study were obtained from local IRB of participating academic sites and from a central IRB (New England IRB, IRB#: 120160610) for private practice sites.

We included patients with a PsA diagnosis who were age 18 years or older, initiating a TNFi between October 1, 2002, and March 21, 2013, had achieved symptom remission/LDA [i.e., Clinical Disease Activity Index (CDAI) score ≤ 10], discontinued their TNFi agent while in LDA, and did not immediately switch to a different bDMARD. For patients with multiple eligible treatment courses, we used the first one. Study patients also had at least 1 followup visit after TNFi discontinuation, and physician- and patient-reported outcomes obtained at this first post-discontinuation visit were compared with those obtained at the TNFi discontinuation visit.

Rebound was defined as CDAI > 10, restart of the discontinued TNFi or initiation of another bDMARD with or without a qualifying CDAI score. We included re-initiation of the discontinued TNFi or initiation of another bDMARD as part of the definition of rebound because patients are evaluated only every 6 months for CDAI. Any drug changes that occur between 2 visits are reported at the following visit where the physician reports type of change and the date that change occurred. Thus, flares that occurred between those regular visits may have been associated with a change in medication management without a corresponding documented disease activity measure.

Other study outcomes evaluated between the TNFi discontinuation and the subsequent followup visit included patient-reported functioning on the modified Health Assessment Questionnaire (mHAQ, scores 0–3), patient’s global assessment of disease severity [visual analog scale (VAS) scores 0–100] and pain (VAS scores 0–100), as well as the physician’s global assessment of disease severity (VAS scores 0–100). For all outcomes, higher scores indicate higher levels of disease activity/severity. CDAI and bDMARD use were also determined for patients at the first post-rebound followup visit.

Patient characteristics at TNFi initiation were summarized [means (SD), ranges, percentages]. Patient- and physician-reported outcomes from the first post-discontinuation followup visit were compared with those recorded at TNFi discontinuation. Kaplan-Meier curves determined time from discontinuation to rebound with followup censored at last available visit for patients without rebound.

RESULTS

We identified 94 patients [57% women, 92% white, mean [SD] age 51.0 (12.4) yrs, 90% privately insured, 16% Medicare-insured] who discontinued TNFi (ADA: 51%, ETN: 21%, IFX: 19%, GOL: 9%) during LDA and had a post-discontinuation visit (Table 1). At TNFi initiation, the mean (SD) disease duration was 8.4 (7.0) years, mean (SD) CDAI was 10.1 (9.3), and 63.7% of patients were in LDA. The majority of patients had prior bDMARD and methotrexate (MTX) use.

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics at TNFi Initiation.

The median (interquartile range) time from TNFi discontinuation to first post-discontinuation visit was 6.8 (5.2–8.1) months. Increases in patient- and physician-reported disease activity/symptoms after discontinuation were statistically significant at p ≤ 0.01, except mHAQ (Figure 1). Most patients (n = 69, 73%) experienced a rebound event (n = 15 CDAI > 10, n = 24 with biologic initiation with nonelevated CDAI, n = 30 both elevated CDAI and biologic initiation) with a median time (95% CI) to rebound of 8.0 months (6.0–12.0; Figure 2). Among patients with a post-rebound visit (59/69), 73% were in remission/LDA at that visit. Overall, 27 of the 59 rebounders resumed use of their original TNFi by the post-rebound visit.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Change in disease activity measures from TNFi discontinuation to first post-discontinuation followup visit. Among the 59 rebounders, the CDAI at rebound was 13.5 ± 10.1 with a mean CDAI at first followup visit of 8.2 ± 8.1. TNFi: tumor necrosis factor inhibitor; CDAI: Clinical Disease Activity Index; PtGA: patient’s global assessment; PGA: physician’s global assessment; mHAQ: modified Health Assessment Questionnaire.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Time to rebound following TNFi discontinuation. Median time from rebound to the first followup visit was 10 months for all 59 rebounders (8.5 mos where rebound was identified by CDAI only, 9.5 mos in those identified by a drug initiation, and 10 mos in those with a drug initiation and an available CDAI). TNFi: tumor necrosis factor inhibitor; CDAI: Clinical Disease Activity Index.

DISCUSSION

The majority (73%) of the 94 patients with PsA whom we studied experienced symptom rebound after discontinuing TNFi therapy following LDA (CDAI ≤ 10) or symptom remission, with half of these patients experiencing rebound within 8 months after treatment discontinuation. Our results are also consistent with those reported in studies of TNFi dose reduction/discontinuation in patients with RA12,13,14,15, and also in a study of disease recurrence in patients with PsA who discontinued conventional or bDMARD after at least 6 months in remission (i.e., no musculoskeletal symptoms and minimal skin disease; mean Psoriasis Area Severity Index: 0.21). In that study (n = 26, 14 MTX monotherapy, 12 TNFi), 77% of patients experienced post-discontinuation recurrence, with a mean time to recurrence of 74.5 ± 72 days16. The authors concluded from this “extraordinary high” rate of recurrence that DMARD discontinuation may not be feasible even in patients who have experienced sustained remission. In a study to assess the feasibility of a treatment withdrawal trial, 11 of 17 patients with minimal PsA disease activity were randomized to treatment withdrawal, and 6 (55%) of these patients experienced a symptom flare, including 2 patients who had been receiving MTX only17. The 4 remaining patients, who had been treated with MTX and a biologic, experienced flare only after the biologic was withdrawn. None of the 6 patients randomized to continue therapy experienced flare. Interestingly, in a study of ADA dose reduction in patients with PsA, mean time to relapse was also 8 months in the minority (11%) who flared18.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European League Against Rheumatism PsA criteria note that the evidence is too limited to recommend discontinuation, dose reduction, or tapering of bDMARD for patients with PsA who have achieved remission/LDA9,19, and the American College of Rheumatology will likely address this issue in its forthcoming 2018 PsA guideline. The significant risk of rebound that we observed offers an important perspective for physicians who are considering TNFi discontinuation for patients who have achieved remission/LDA, and may provide a key piece of data in discussing the most likely potential outcome with their patients who are considering TNFi discontinuation.

Our study provides unique real-world data on the incidence of rebound after patients with PsA who discontinued TNFi therapy after achieving remission/LDA. The study population included patients from across the United States, and represents experience in the routine care setting. As an observational cohort, patient followup was based on routine care rather than mandatory visit schedules. The registry was created prior to the development of the current validated PsA measures; instead it collected the CDAI. Thus, patients may have initiated TNFi therapy while in LDA because of nonarticular symptoms such as skin disease and enthesitis. Of note, we characterized rebounding of symptoms based on an evaluation at the time of a clinical visit. It is possible that patients may have had flare symptoms for some time before presenting to the provider, in which case we have overestimated time to flare. Additionally, mild flares not requiring use of biologics would have been missed. Also, reasons for discontinuation and initiation of medications were unavailable. Finally, while this is the largest cohort studied to date, our sample size is modest, which may limit the stability of our findings. Our results cannot be considered definitive, but they indicate that the true risk of rebound following TNFi discontinuation is likely substantial, and that continuation of bDMARD therapy may well play a key role in helping patients with PsA remain in remission/LDA.

Footnotes

  • Sponsored by Corrona LLC. Corrona LLC has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, BMS, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche, and UCB. LRH is an employee and shareholder of Corrona LLC, and has a research grant to the University of Massachusetts Medical School from Pfizer. BSS, DHC, and AM are employees and shareholders of Amgen Inc. SR and WM are employees of Corrona LLC. SWW is a consultant of Amgen Inc. JDG is an employee and shareholder of Corrona LLC, and a consultant of Eli Lilly, Genentech, Janssen, Novartis, and Pfizer. CJE is an employee of Corrona LLC and an advisory board member for Merck.

  • Accepted for publication July 19, 2017.

REFERENCES

  1. 1.↵
    1. Lloyd P,
    2. Ryan C,
    3. Menter A
    . Psoriatic arthritis: an update. Arthritis 2012;2012:176298.
    OpenUrlPubMed
  2. 2.↵
    1. Gelfand JM,
    2. Gladman DD,
    3. Mease PJ,
    4. Smith N,
    5. Margolis DJ,
    6. Nijsten T,
    7. et al.
    Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2012;53:573.
    OpenUrl
  3. 3.↵
    1. Gottlieb A,
    2. Korman NJ,
    3. Gordon KB,
    4. Feldman SR,
    5. Lebwohl M,
    6. Koo JY,
    7. et al.
    Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851–64.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Wilson FC,
    2. Icen M,
    3. Crowson CS,
    4. McEvoy MT,
    5. Gabriel SE,
    6. Kremers HM
    . Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 2009;36:361–7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Jafri K,
    2. Bartels CM,
    3. Shin D,
    4. Gelfand JM,
    5. Ogdie A
    . Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res 2017;69:51–7.
    OpenUrl
  6. 6.↵
    1. Boehncke WH,
    2. Menter A
    . Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol 2013;14:377–88.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Verstappen SM,
    2. Watson KD,
    3. Lunt M,
    4. McGrother K,
    5. Symmons DP,
    6. Hyrich KL;
    7. BSR Biologics Register
    . Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:1570–7.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Wallenius M,
    2. Skomsvoll JF,
    3. Koldingsnes W,
    4. Rodevand E,
    5. Mikkelsen K,
    6. Kaufmann C,
    7. et al.
    Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009;68:685–9.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gossec L,
    2. Smolen JS,
    3. Ramiro S,
    4. de Wit M,
    5. Cutolo M,
    6. Dougados M,
    7. et al.
    European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Kang EJ,
    2. Kavanaugh A
    . Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis 2015;6:194–203.
    OpenUrlCrossRef
  11. 11.↵
    1. Yang ZS,
    2. Lin NN,
    3. Li L,
    4. Li Y
    . The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol 2016;51:240–7.
    OpenUrl
  12. 12.↵
    1. Haschka J,
    2. Englbrecht M,
    3. Hueber AJ,
    4. Manger B,
    5. Kleyer A,
    6. Reiser M,
    7. et al.
    Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016;75:45–51.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Kavanaugh A,
    2. Lee SJ,
    3. Curtis JR,
    4. Greenberg JD,
    5. Kremer JM,
    6. Soto L,
    7. et al.
    Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis 2015;74:1150–5.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Smolen JS,
    2. Nash P,
    3. Durez P,
    4. Hall S,
    5. Ilivanova E,
    6. Irazoque-Palazuelos F,
    7. et al.
    Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918–29.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. van Herwaarden N,
    2. den Broeder AA,
    3. Jacobs W,
    4. van der Maas A,
    5. Bijlsma JW,
    6. van Vollenhoven RF,
    7. et al.
    Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014:CD010455.
  16. 16.↵
    1. Araujo EG,
    2. Finzel S,
    3. Englbrecht M,
    4. Schreiber DA,
    5. Faustini F,
    6. Hueber A,
    7. et al.
    High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis 2015;74:655–60.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Moverley A,
    2. Coates L,
    3. Marzo-Ortega H,
    4. Waxman R,
    5. Torgerson D,
    6. Cocks K,
    7. et al.
    A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)). Clin Rheumatol 2015;34:1407–12.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Cantini F,
    2. Niccoli L,
    3. Cassarà E,
    4. Kaloudi O,
    5. Nannini C
    . Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics 2012;6:201–6.
    OpenUrlPubMed
  19. 19.↵
    1. Coates LC,
    2. Murphy R,
    3. Helliwell PS
    . New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol 2016;174:1174–8.
    OpenUrl
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 45, Issue 1
1 Jan 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity
Leslie R. Harrold, Bradley S. Stolshek, Sabrina Rebello, David H. Collier, Alex Mutebi, Sally W. Wade, Wendi Malley, Jeffrey D. Greenberg, Carol J. Etzel
The Journal of Rheumatology Jan 2018, 45 (1) 78-82; DOI: 10.3899/jrheum.161567

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity
Leslie R. Harrold, Bradley S. Stolshek, Sabrina Rebello, David H. Collier, Alex Mutebi, Sally W. Wade, Wendi Malley, Jeffrey D. Greenberg, Carol J. Etzel
The Journal of Rheumatology Jan 2018, 45 (1) 78-82; DOI: 10.3899/jrheum.161567
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

PSORIATIC ARTHRITIS
ANTIRHEUMATIC AGENTS
TUMOR NECROSIS FACTOR-α

Related Articles

Cited By...

More in this TOC Section

  • Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis
  • Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases
  • Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis
Show more Psoriatic Arthritis

Similar Articles

Keywords

  • psoriatic arthritis
  • antirheumatic agents
  • TUMOR NECROSIS FACTOR-Α

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire